Characteristics and outcomes in sero-positive late-onset rheumatoid arthritis patients who start a new disease modifying anti-rheumatic drug

被引：0
|
作者：
Ranganath, V. K. [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
ARTHRITIS RESEARCH & THERAPY | 2005年 / 7卷
关键词：
Rheumatoid Arthritis; Rheumatoid Arthritis Patient; Propensity Score; Rheumatoid Factor; Generalize Match;
D O I：
10.1186/ar1687
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [21] Gene expression of Interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy
    Khalid, Sabeen
    Yousaf, Muhammad Javad
    Rashid, Amir
    Khan, Saleem Ahmad
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2019, 35 (03) : 802 - 806
  • [22] Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Enrique Machado-Alba, Jorge
    Felipe Ruiz, Andres
    Enrique Machado-Duque, Manuel
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2014, 36 (06): : 396 - 401
  • [23] Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis
    Akter, Ripa
    Maksymowych, Walter P.
    Martin, M. Liam
    Hogan, David B.
    CANADIAN GERIATRICS JOURNAL, 2020, 23 (02) : 184 - 189
  • [24] Influence of triple disease modifying anti-rheumatic drug therapy on carotid artery inflammation in drug-naive patients with recent onset of rheumatoid arthritis
    Haavisto, Matti
    Saraste, Antti
    Pirila, Laura
    Hannukainen, Jarna C.
    Kalliokoski, Kari K.
    Kirjavainen, Anna
    Kemppainen, Jukka
    Mottonen, Timo
    Knuuti, Juhani
    Yli-Kerttula, Timo
    Roivainen, Anne
    RHEUMATOLOGY, 2016, 55 (10) : 1777 - 1785
  • [25] Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis
    Cummins, L.
    Katikireddi, V. S.
    Shankaranarayana, S.
    Su, K. Y. C.
    Duggan, E.
    Videm, V.
    Pahau, H.
    Thomas, R.
    INTERNAL MEDICINE JOURNAL, 2015, 45 (12) : 1266 - 1273
  • [26] Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers
    Shimada, Hiromi
    Kameda, Tomohiro
    Kanenishi, Kenji
    Miyatake, Nobuyuki
    Nakashima, Shusaku
    Wakiya, Risa
    Kato, Mikiya
    Miyagi, Taichi
    Mansour, Mai Mahmoud Fahmy
    Hata, Toshiyuki
    Kadowaki, Norimitsu
    Dobashi, Hiroaki
    CLINICAL RHEUMATOLOGY, 2019, 38 (05) : 1453 - 1458
  • [27] Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers
    Hiromi Shimada
    Tomohiro Kameda
    Kenji Kanenishi
    Nobuyuki Miyatake
    Shusaku Nakashima
    Risa Wakiya
    Mikiya Kato
    Taichi Miyagi
    Mai Mahmoud Fahmy Mansour
    Toshiyuki Hata
    Norimitsu Kadowaki
    Hiroaki Dobashi
    Clinical Rheumatology, 2019, 38 : 1453 - 1458
  • [28] Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs
    Meroni, P. L.
    Zavaglia, D.
    Girmenia, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (02) : 317 - 328
  • [29] German guidelines for the treatment of rheumatoid arthritis with disease modifying anti-rheumatic drugs - What is new?
    Fiehn, Christoph
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2020, 145 (07) : 474 - 479
  • [30] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Xerxes Pundole
    Natalia V. Zamora
    Harish Siddhanamatha
    Heather Lin
    Jean Tayar
    Leung Cheuk Hong
    Liang Li
    Maria E. Suarez-Almazor
    Clinical Rheumatology, 2020, 39 : 787 - 794
12345